StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Wed, 26 Aug 2026 06:42:28 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $35.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).

The analyst commented: "This week, Corbus, in collaboration with CSPC , published a detailed preclinical characterization of CRB-701 in Cancer Research Communications that, in our view, provides the clearest mechanistic explanation to date for why the ADC may behave differently from enfortumab vedotin (EV), despite targeting the same antigen and carrying the same MMAE payload. The differentiation starts with the construct itself. CRB-701 uses mTGase-mediated, site-specific conjugation at Q294 of each heavy chain to generate a highly homogeneous ADC with a mean

Form 4 Corbus Pharmaceuticals For: Aug 16 Filed by: Nicacio Leonardo Viana

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938354.html

Form 4 Corbus Pharmaceuticals For: Aug 16 Filed by: Nicacio Leonardo Viana

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938354.html

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930071.html

Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930071.html

Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho

Thu, 13 Aug 2026 06:38:09 -0400

(Updated - August 13, 2026 6:38 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $33.00 (from $34.00) while maintaining a Outperform rating.

The analyst commented: "CRBP reported 2Q results last week, for which we saw no material updates. While we lower our PT to $33 (vs. $34 prior) on minor model updates, our main focus remains progress with CRBP's two pipeline candidates, each of which has an important catalyst in September: (1) for CRB-913 (a CB1 inverse agonist for obesity), a top-line P1b CANYON-1 study data announcement; and (2) for lead asset CRB-701 (a

Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho

Thu, 13 Aug 2026 06:38:09 -0400

(Updated - August 13, 2026 6:38 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $33.00 (from $34.00) while maintaining a Outperform rating.

Form 4 Corbus Pharmaceuticals For: Aug 11 Filed by: Saxena Nishant C

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913447.html

Form 4 Corbus Pharmaceuticals For: Aug 11 Filed by: Saxena Nishant C

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913447.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Cohen Yuval

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898476.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Cohen Yuval

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898476.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Moran Sean F.

Mon, 10 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260810/26898460.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Moran Sean F.

Mon, 10 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260810/26898460.html

Form 424B5 Corbus Pharmaceuticals

Fri, 07 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260807/26891640.html

Form 424B5 Corbus Pharmaceuticals

Fri, 07 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260807/26891640.html

Form 144 Corbus Pharmaceuticals Filed by: Stifel, Nicolaus & Company, Inc CIAS /FA

Fri, 07 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260807/26891418.html

Form 144 Corbus Pharmaceuticals Filed by: Stifel, Nicolaus & Company, Inc CIAS /FA

Fri, 07 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260807/26891418.html

Form 144 Corbus Pharmaceuticals Filed by: Stifel, Nicolaus & Company, Inc CIAS /FA

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890933.html

Form 144 Corbus Pharmaceuticals Filed by: Stifel, Nicolaus & Company, Inc CIAS /FA

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890933.html

Corbus Pharmaceuticals (CRBP) PT Lowered to $48 at Oppenheimer

Fri, 07 Aug 2026 08:04:57 -0400

Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $48.00 (from $52.00) while maintaining a Outperform rating.

Form 10-Q Corbus Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884885.html